StemCell Therapy

Wall Street Journal (subscription)

Nasdaq Slips as Biotechnology Shares Decline Wall Street Journal (subscription) Declines in biotechnology shares dragged down the Nasdaq Composite, pressuring an index that has soared so far this year. The Nasdaq fell 0.4% Thursday but is up more than 8% in 2017, outperforming both the Dow Jones Industrial Average and the S&P ... and more »

See the original post here:
Nasdaq Slips as Biotechnology Shares Decline - Wall Street Journal (subscription)

DES MOINES, Iowa & DAVIS, Calif.--(BUSINESS WIRE)--

Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd., NASDAQ: SEED), an agricultural biotechnology trait and seed provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a California-based company that develops and commercializes agricultural productivity traits and nutritional products, today announced their collaboration to achieve the first-ever export of a key corn biotechnology product developed in China to the United States for completion of global regulatory trials.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170222005379/en/

The successful movement of this corn seed, containing an insect resistance/herbicide tolerance trait discovered and developed in China, to the Arcadia greenhouse represents a key milestone in Origins strategic business plan to achieve global regulatory approvals for cultivation and international grain movement.

This first-of-its-kind export validatesOrigins leading position in China biotech and its close alignment with Chinese ministries leading the transformation of the domestic seed industry. Combining Origins robust pipeline of value-added Chinese traits and elite corn germplasm with Arcadias research and development infrastructuredemonstrates our plan to capture a sizeable piece of Chinas estimated billion-dollar corn seed trait market, said Bill Niebur, Origin chief executive officer. As a leader in agtech focused on modernizing the traditional corn seed market, our international team remainsfocused on accelerating research and development to improve the lives of Chinese farmers.

Arcadia and Origin signed an agreement under which Arcadia will assist Origin in developing information for submission to regulatory authorities in the U.S., China and other countries for the approval of their traits in corn. This project involves production of inbred and hybrid seed lines under quarantine conditions in Arcadia greenhouses.

Arcadia has the proven expertise to bring traits through the regulatory process successfully and efficiently, said Raj Ketkar, Arcadias president and CEO. We have conducted hundreds of studies in the laboratory, greenhouse and field to gain regulatory approvals for various traits in major crops, and we have a strong regulatory team that has developed complete regulatory dossiers in multiple countries. This collaboration with Origin is an example of how our partners can leverage these capabilities to accelerate the commercialization of novel ag biotech traits.

Ultimately, this milestone achievement will create more choices and opportunities for farmers, said Jihong Liang, Origin chief technology officer. This is an important achievement, showcasing Origins competitive advantage in science and global reach through collaborations inside China and beyond its borders. Origin is leading the way in gaining regulatory approvals for this critical advanced technology globally to drive future business growth.

Origins investment and focus aligns tightly with Chinas 13th Five Year Plan, which calls for the modernization of agriculture as the foundation for building a prosperous society. The Chinese government, including the Ministry of Agriculture (MOA) and Chinese Academy of Agricultural Sciences (CAAS), has advanced a policy vision to facilitate seed industry innovation, improve the competitiveness of the Chinese ag tech industry and cultivate new seed varieties for farmers around the world. Through these actions, China has shown strong commitment to advancing its ag industry through new advances in biotechnology. Origin anticipates China commercialization of corn biotechnology at the end of this decade.

About Origin Agritech Ltd.

Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is Chinas leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin Agritechs phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please visit the Companys website at: http://www.originseed.com.cn or http://www.originseed.com.cn/en/.

Read More

Arcadia Biosciences, Inc.

Based in Davis, Calif., Arcadia Biosciences (RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadias agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadias nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit http://www.arcadiabio.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as expect, anticipate, intend, plan, believe, seek, see, will, would, target, similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the companys control. Some of the important factors that could cause the companys actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company's intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170222005379/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170222005379/en/

Originally posted here:
Origin, Arcadia Announce China Biotechnology Collaboration in Corn - Yahoo Finance

Innovation not necessarily comprises a scientific breakthrough but seeks the immediacy of needs to be acknowledged, asserts Rabindra Mohan Sapkota, 43, who is the chairman of Shikhar Biotech established in 2000. In conversation with Republicas Sonam Lama, he shares some of his insights on initiating the first biotechnological company in Nepal, followed by its different setbacks.

Tell us about Shikhar Biotech? Shikhar Biotech is pioneer antibody production company in Nepal which was initiated by the parent biotech company based in the United Kingdom. Our company is a spin-off of the British-Nepali venture Everest Biotech Limited, UK. We aim to manufacture and deliver the highest quality reagents and services to life-science researchers and other biotech companies worldwide.

How is Shikhar Biotech different from other biotech companies? Yes. Many experiments in Nepal are carried out on plant biotechnology but we have been conducting a specific operation on producing and manufacturing goat antibodies. With a smooth manufacture and delivery of more than 3000 antibodies till date, we believe we are attained a renowned space in the international market with our products being on long term demand. We have a strong track record of testing thousands of high quality goat polyclonal antibodies on behalf of our previous parent company. This experience has enabled us to offer this service now to other companies or researchers at competitive prices without any compromise in quality.

How does Shikhar Biotech benefit Nepal? With our company being recognized as an independent one, it has helped acquiring first hand contribution to boost the economy of Nepal. Our rigorous research and hands on activities have increased the growth in productivity. Our operations run further with promoting goat rearing in several villages such as Taulung which has earned a good source of income for the village farmers. On this note, we have gradually been able to provide technological materials such as cell lines to students of Kathmandu and Tribhuwan Universities. We are now extending our work to developing new products within Nepal.

What were the setbacks of initiating a pioneer company in Nepal? There were certain challenges since its inception as there was a congested market with people being highly unaware of biotechnological studies. So we primarily had to struggle for an access to the market outside Nepal. Moreover, limited amount of revenue and acute lack of investments occurred with the scarcity of raw materials and services. In context of Nepal, the financial crisis has been lagging us behind. However, in the case of availability of ample resources, we still fall short for research, innovation, and awareness.

What are your further plans? One of our long term plans is to include the development of testing material of vitamin D. This tester is used to detect the content of Vitamin D in a human body through antibody platform. In order to make it easily accessible and cost cheaper in Nepal, the research on producing diagnostic kits have been under high consideration. We have been conducting researches on developing the glucose tester in Nepal which would serve Nepal in the long run.

Go here to read the rest:
Biotechnology company is introducing Nepal to the world market - Republica

Generex Biotechnology Corporation (OTCMKTS:GNBT) is a micro-cap biotech player that has been on the rise of late despite an avalanche of growing debt and no clear route to near term monetization. But such is the case quite often in this sector, even in the case of the best opportunities. GNBT stockis moving higher in recent days following a couple catalysts.

In the first case, the company announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc, a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative treatments and therapies, primarily for rare and orphan disease. Initial product development efforts are focused on Sickle Cell Disease (SCD), a genetic disorder. In the second case, the company just announced that it has achieved the elimination of its outstanding derivative securities.

Generex Biotechnology Corporation (OTCMKTS:GNBT) trumpets itself as a company engaged in the research, development, and commercialization of drug delivery systems and technologies.

As the company states, Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Companys proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Companys proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex.

The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.

According to company materials, Hema Diagnostic Systems, LLC (www.rapid123.com) is a rapidly growing biotechnology company involved in the development, manufacture, assembly, and distribution of diagnostics targeting primary as well as orphan infectious diseases. Hema Diagnostic Systems continues to expand its product line to meet the needs of the worldwide market. Point-of-Care test devices are made simple to use and are highly cost effective when incorporated into Hema Diagnostic Systems patented and patent pending delivery systems. The Rapid 1-2-3 Hema EXPRESS is a novel delivery system that is self-contained and easy to use.

Find outwhen GNBT stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

In thinking about the potential benefits of a controlling position in Emmaus, Dr. Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus and Executive Chairman of Generex commented: R&D efforts continue apace at Emmaus, as evidenced by these new patents securing our intellectual property portfolio. We are pleased to add diverticulosis and diabetes as prospective new indications for our PGLG product which we are currently developing for the treatment of SCD.

Joseph Moscato, Generex President & CEO, stated: I am gratified by the confidence Emmaus has expressed in Generex in providing this leeway to allow us to consummate the reorganization of our capital structure which will set the stage for our future successes.

That said, our sense is that the biggest catalyst in recent action may actually be the cap table move through undercutting the companys derivative liabilities.

As noted in the companys most recent release, the consequent reduction in the number of shares coming into the market and the termination of the attendant price protection provisions will unburden the Company. In addition, the elimination of the derivative liability will greatly improve the Companys balance sheet. Thus unencumbered, and with a reinvigorated management team and Board of Directors, the Company will proceed to execute its business plans and to attract value investors.

The chart shows just under 290% piled on for shareholders of the listing during the trailing month. Market participants may want to pay attention to GNBTstock. Generex has a track record that includes a number of dramatic bounces. Whats more, the company has witnessed a pop in interest, as transaction volume levels have recently pushed just shy of 410% above its longer run average levels. Since we last covered the name, the stock has moved 58% higher.

Now commanding a market cap of $15.8M, GNBT has virtually no cash on the books, which compares with a mountain of current liabilities, in excess of $9 million. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. This may be a very interesting story and we will look forward to updating it again soon. For continuing coverage on shares of GNBT stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

See the rest here:
Generex Biotechnology Corporation (OTCMKTS:GNBT) Pushes Higher on New Catalysts - The Oracle Dispatch

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Cellect Biotechnology Ltd. (Nasdaq: APOP) announced today positive final results from its clinical trial of ApoGraft in healthy donors. The studys primary objective was to validate the Company's propriety method of stem cell selection by going through the process of production and characterization with ApoGraft, and was conducted on samples obtained in collaboration with two leading medical centers in Israel, The Schneider Children's Medical Center and the Rambam Medical Center.

Cellects technology enables the use of stem cells for regenerative therapies by eliminating mature cells while leaving the stem cells unharmed using a natural process occurring in the human body, apoptosis (programed cell death), which orders cells to commit suicide. Cellects validated scientific platform, and the focus of its 7 families of patents, is that the apoptosis command destroys primarily mature cells, while stem cells remain alive and flourishing. This process allows for natural enrichment of stem cells, thus enabling stem cell-based therapies or transplantation to possess an abundance of quality stem cells with little to no risk of rejection or other complications, such as Graft versus Host Disease (GvHD).

The study included 104 healthy donors of blood stem cells. The samples (collected under approval of Helsinki committees) represented 5% of a graft used for transplantation into patients. The grafts were processed allowing stem cell production for transplantation with Cellects ApoGraft. The use of the ApoGraft resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

Dr. Yaron Pereg, Cellects Chief Development Officer, commented: These results from processing human stem cells for bone marrow transplantation using ApoGraft clearly demonstrated that Cellects proprietary platform could improve the outcome of stem cell transplantations in patients suffering from hematological malignancies.

More:
Cellect Biotechnology (APOP) Announces Positive Results of Clinical Trial of ApoGraft - StreetInsider.com

MPs on Tuesday clashed with biotechnology researchers over the lifting of the GMO ban.

The law makers dismissed a call to have the ban lifted and called for development of home grown biotechnology solutions rather than imposing "foreign ideologies".

Our researchers should focus on home grown technologies that address some of the challenges farmers are facing such as aflatoxin, drought tolerant crop varieties and the stem borer pest, said Agriculture Parliamentary committee chair Noor Mohammed.

He assured local scientists that as long as they focus on need based research, the committee will lobby the government to allocate more resources.

Mohammed made the remarks during a consultative meeting between the committee and biotechnology stakeholders.

He noted that there has not been any scientific evidence on the safety of GMOs, or any guarantee that it can offer a solution to food insecurity in the country.

Read: University students want government to issue licence of GMO maize

Also read: State launches GMO labelling mark amid jitters of effect on existent ban

There is no research in the world specifically stating on the safety of the technology. Let any scientist give evidence in Kenya own up and that GMO is safe for human consumption, he said.

Mohammed stated that MPs remarks should not be construed to mean that the political class in the country is against the introduction of GMO, but warned the researchers and other experts against issuing conflicting statements.

He said all the Parliamentary committees - health, agriculture, environment, education - and all the biotechnology researchers need to work together with a view to providing a common approach regarding the issue.

Dr Margaret Karembu emphasised on the need by the government to allow application of GMO as one of the tools to taming food insecurity and enhancing agricultural productivity.

Any country that does not give opportunity to researcher will forever rely on other peoples products. GMOs have been proven safe by the World Health Organization and other global biotechnology players, said Karembu.

Willy Tonui, the National Biosafety Authority CEO, assured Kenyans that there is no GMO product in the market and that the government is vigilant in monitoring all the foreign materials that are being imported in the county.

Excerpt from:
MPs clash with biotechnology researchers over GMO ban - The Star, Kenya

Cellect Biotechnology Ltd. (NASDAQ: APOP)

Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we've seen a continuation of strong movement. Below, we'll talk about what we're seeing from the stock, why, and what we'll be watching for with regard to APOP ahead.

As mentioned above, Cellect Biotechnology is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. Throughout the morning, we've seen a continuation of gains. At the moment (10:52), APOP is trading at $6.91 per share after a gain of $1.08 per share (18.52%) thus far today.

As is almost always the case, our partners at Trade Ideas were the first to send the alert that APOP was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn't take long to uncover the story. The gains are ultimately the result of a positive data release.

Early this morning, Cellect Biotechnology released positive results from its clinical trial of ApoGraft(TM). The point of the study was to validate the company's proprietary method for stem cell selection. To do so, the company went through the process of production and characterization through ApoGraft. In the announcement, investors learned that the company met its primary endpoint in this study.

Moving forward, the CNA Finance team will continue to keep a close eye on APOP. In particular, we're following ongoing work with regard to ApoGraft as well as the rest of the company's pipeline. We'll keep a close eye on the news and continue to bring it to you as it breaks!

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

View post:
Cellect Biotechnology (APOP) Stock: Gaining Big On Positive Clinical Data - CNA Finance (press release)

Minuteman HS Receives Biotechnology Lab Grant Patch.com From Minuteman HS:Minuteman High School has landed another major grant from the Massachusetts Life Sciences Center to help upgrade its Biotechnology program. The $108,172 competitive grant will enable the school to outfit its Biotechnology lab with ... and more »

Read more:
Minuteman HS Receives Biotechnology Lab Grant - Patch.com

Puma Biotechnology Inc s chart and data analysis indicates that the stock price has dropped -14.54% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -29.98% . Looking at the past 52 week period, the stock price is down -12.97% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Puma Biotechnology Inc has a positive value of 4.53 compared to overall market.Puma Biotechnology, Inc. is having a Relative Strength Index of 68.39 which indicates the stock is not yet over sold or over bought based on the technical indicators.

For the current week, the company shares have a recommendation consensus of Buy. Puma Biotechnology Inc (NYSE:PBYI) has climbed 10.43% in the past week and advanced 24.81% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 8.78% and the outperformance has advanced to 20.57% for the last 4 weeks period.

Company has reported several Insider transactions to the SEC, on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at 33.24 per share price.On Jan 24, 2017, Charles R Eyler (officer ) sold 820 shares at 33.24 per share price.On Jan 24, 2017, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 2,293 shares at 33.24 per share price.

Puma Biotechnology Inc (NYSE:PBYI) rose 7.76% or 2.9 points on Friday and made its way into the gainers of the day. After trading began at $37.25 the stock was seen hitting $40.5 as a peak level and $36.7 as the lowest level. The stock ended up at $40.25. The daily volume was measured at 1,377,113 shares. The 52-week high of the share price is $73.27 and the 52-week low is $19.74. The company has a market cap of $1,482 million.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.

Go here to see the original:
Stock Price of Puma Biotechnology Inc (PBYI) Increases 10.43% - Highland Mirror

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016, posting a loss of more than 20%, has started posting gains again, and is looking like the rally may be poised to continue. The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (NYSEARCA:XBI), is up over 17%).

The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to "speed the approval of life-saving medications" and "cutting the red tape at the FDA." That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies.

One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers Squibb (NYSE:BMY). A StreetInsider article from this week called the company "in play" and listed Roche (OTCQX:RHHBY), Novartis (NYSE:NVS), Gilead (NASDAQ:GILD) and Pfizer (NYSE:PFE) all as potential buyers. Acadia Pharmaceuticals (NASDAQ:ACAD) could also be up for grabs with Biogen (NASDAQ:BIIB) rumored to be a possible bidder. In its quarterly analyst meeting, Amgen's (NASDAQ:AMGN) CEO Bob Bradway discussed how his company was going to be on the lookout for acquisitions, both big and small.

Even Gilead, the big biotech that just caught Wall Street off guard when it significantly lowered 2017 revenue guidance due to weak sales in its hepatitis C drugs, even provided some reason for optimism. The stock dropped roughly 10% on its weak forecast, from a pre-earnings level of around $73, down to a post-announcement low in the $65 area. Since then, however, it has, somewhat surprisingly, begun rallying anew. The stock closed Friday at $70, gaining back nearly of what was lost. Does this signal something of a capitulation point and indicate that buyers are ready to return?

From a technical standpoint, the fund just broke out to the upside from a wedge pattern that has been forming over the past several months.

I wrote earlier this month that I felt the Biotech ETF could close out February above $300 if it could break through the resistance level around $285. It has and now it feels like that $300 level is well within reach.

Despite its rally so far this year, the fund is still about 13% off of its 2016 highs and 26% off of its all-time highs. Valuations in the sector look very reasonable right now as well. Thomson Reuters estimates put the forward P/E of the sector at less than 13, a level it hasn't seen in several years.

Gilead's results notwithstanding, the Q4 earnings season has been pretty good for biotech. Big players such as Amgen, Celgene (NASDAQ:CELG), Illumina (NASDAQ:ILMN) and Vertex Pharmaceuticals (NASDAQ:VRTX) - all top 10 holdings in the fund - popped strongly after announcing earnings. If the sector can continue posting generally good revenue and earnings results and get a little help from the White House along the way, this could be a nice spot to add a few shares.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Follow this link:
This Biotech ETF Looks Primed To Rally Again - iShares Nasdaq ... - Seeking Alpha

With five U.S. patents issued and dozens more filed and pending around the world, On Target Laboratories LLC is working to advance its revolutionary fluorescent imaging technology that could help surgeons pinpoint and remove more cancerous tissues than has ever been possible while preserving more healthy tissue for patients.

Headquartered at Purdue Research Park of West Lafayette, the company is developing a series of molecules, which, when administered intravenously, show promise in targeting many types of cancer cells, said Dr. Sumith Kularatne, On Targets vice president of research and development.

In addition to our current U.S. patents, we have 11 more either filed or pending in the U.S., Kularatne said. We have another 33 patents pending worldwide. These patents are very important in helping us move our discoveries to the public where they can help people.

These molecules carry a fluorescent dye and target diseased cells, including cancer, enabling surgeons to better diagnose and remove the disease while avoiding collateral damage to healthy tissue such as nerves.

OTL38 is a novel compound consisting of a folic acid-targeting molecule, or ligand, linked to a near-infrared dye. Following current clinical trial protocols, OTL38 is injected two hours before surgery and is intended to bind to diseased tissue, including several cancers, involving lung, ovarian, and renal. The goal of this technology is to allow the surgeon to see hard-to-detect, small cancer lesions or diseased lymph nodes that might otherwise be missed through the use of a NIR (near-infrared) camera. OTL ligands are designed to enhance the view in real time, and if proven successful, we believe may be an important addition to image-guided surgery.

We have a very robust portfolio of intellectual property (IP), said Martin Low, the companys chief executive officer. We believe, with this proprietary technology, we will enable surgeons in removing any solid tumor cancer.

In addition to cancer, On Target technology has shown promise in targeting infectious diseases and inflammatory diseases.

One of the patents issued for OTL38, On Targets primary molecule, is for the targeting of inflammatory diseases. Another pending patent is for the targeting of some infectious diseases.

In addition to OTL38, On Targets other molecules include: OTL78 which has four patents pending. Its shown promise for prostate, brain, liver, breast and colorectal cancers. OTL81 which has a pending patent. Its shown promise for gastric and thyroid cancers. OTL338 which has a pending patent. Its shown promise for pancreatic, colorectal and kidney cancers as well as tumors under hypoxic conditions. OTL228 which has three patents pending. Its shown promise for ovarian, lung, breast, pituitary and other cancers as well as rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.

On Targets patenting process has moved very quickly due to the strength of the science involved as well as the level of communication between the science and legal teams, Kularatne said.

Normally the patenting process can take years. But our initial five patents were issued in two years, Low said. Pending completion of clinical trials, commercialization of OTL38 for ovarian cancer patients is scheduled for early 2019 and for lung cancer patients in 2021.

While we are working to protect our IP, the real goal here is to save lives, Kularatne said. Cancer may start the fight. We want to finish it.

See the original post:
Flourescent biotechnology for high lighting solid cancer for more complete surgical removal - Next Big Future

February 20, 2017 6:42am NASDAQ:IBB

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue.

The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (XBI), is up over 17%).

The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to speed the approval of life-saving medications and cutting the red tape at the FDA. That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies.

One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers Squibb (BMY). A StreetInsider article from this week called the company in play and listed Roche (RHHBY), Novartis (NVS), Gilead (GILD) and Pfizer (PFE) all as potential buyers. Acadia Pharmaceuticals (ACAD) could also be up for grabs with Biogen (BIBB) rumored to be a possible bidder. In its quarterly analyst meeting, Amgens (AMGN) CEO Bob Bradway discussed how his company was going to be on the lookout for acquisitions both big and small.

Even Gilead, the big biotech that just caught Wall Street off guard when it significantly lowered 2017 revenue guidance due to weak sales in its hepatitis C drugs, even provided some reason for optimism. The stock dropped roughly 10% on its weak forecast, from a pre-earnings level of around $73 down to a post-announcement low in the $65 area. Since then, however, it has, somewhat surprisingly, begun rallying anew. The stock closed Friday at $70, gaining back nearly of what was lost. Does this signal something of a capitulation point and indicate that buyers are ready to return?

From a technical standpoint, the fund just broke out to the upside from a wedge pattern that has been forming over the past several months.

I wrote earlier this month that I felt the Biotech ETF could close out February above $300 if it could break through the resistance level around $285. It has and now it feels like that $300 level is well within reach.

Despite its rally so far this year, the fund is still about 13% off of its 2016 highs and 26% off of its all-time highs. Valuations in the sector look very reasonable right now as well. Thomson Reuters estimates put the forward P/E of the sector at less than 13, a level it hasnt seen in several years.

Gileads results notwithstanding, the Q4 earnings season has been pretty good for biotech. Big players such as Amgen, Celgene (CELG), Illumina (ILMN) and Vertex Pharmaceuticals (VRTX) all top 10 holdings in the fund popped strongly after announcing earnings. If the sector can continue posting generally good revenue and earnings results and get a little help from the White House along the way, this could be a nice spot to add a few shares.

The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) closed at $294.35 on Friday, up $1.37 (+0.47%). Year-to-date, IBB has gained 10.92%, versus a 5.17% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

About the Author: David Dierking

David Dierking is a freelance writer focusing primarily on ETFs, mutual funds, dividend income strategies and retirement planning. He has spent more than 20 years in the financial services industry and his background includes experience in investment management, portfolio analytics and asset/liability management at both BMO Financial Group and Strong Capital Management.

He has written for Seeking Alpha, Motley Fool, ETF Trends and Investopedia and was also included in the panel for ETFReference.coms 101 ETF Investing Tips from the Experts. He has a B.A. in Finance from Michigan State University and lives in Wisconsin with his wife and two daughters.

You can connect with David on Twitter and LinkedIn. Also be sure to visit his new website, ETFFocus.com.

Tags: biotech david dierking NASDAQ:IBB

Categories: NASDAQ:IBB

More here:
This Biotech ETF Looks Primed To Rally Again - ETF Daily News (blog)

The Associated Press

DECATUR -- Two Illinois lawmakers have proposed a plan to offer tax credits to biotechnology businesses in hopes of boosting agricultural jobs in central Illinois.

The legislation, introduced by Republican state Sen. Chapin Rose of Mahomet and Democratic state Sen. Andy Manar of Bunker Hill, would provide incentives to produce and sell new renewable products made from biomass and other renewable sources, the Herald & Reviewreported.

Manar said the state is strategically poised to lead the development of new renewable products.

"We have leading biotechnology companies, large and small, that are leading research and development efforts on these innovative products, and we have critical mass in infrastructure to produce and transport these renewables around the world," Manar said.

Rose said there's potential for Decatur to be at the center of a new $20 billion biotechnology industry. He said the intent is to utilize Decatur's production and shipping capacity through the Midwest Inland Port along with the Integrated Bioprocessing Research Lab in Urbana.

"The potential for jobs is here," Rose said. "We have something no one else has to offer. This bill will help us capitalize on this and bring these jobs to central Illinois."

The proposed legislation would provide a state tax credit to Illinois companies that produce and sell new manufactured products made from bio-based molecules of biomass feedstocks. Those products, including renewable chemicals and food additives, represent the next generation of advanced biofuels.

"These new bio-based products offer great potential to the Illinois economy across the entire state," said Warren Ribley, president and CEO of Biotechnology Innovation Organization, which is among the organizations leading the efforts in Illinois. "We need to lead now by leveraging our tremendous assets or forever be playing catch-up."

The plan's chances in the state legislature are uncertain.

Illinois' corporate tax incentive program has been under scrutiny recently with critics calling it too expensive and favorable to large businesses. Last month Republican Gov. Bruce Rauner signed an extension of the program through April but has called for replacing the program, known as EDGE, or Economic Development for a Growing Economy.

Rauner's spokeswoman Eleni Demertzis saidMondaythat the bill is "under review."

Follow this link:
Illinois senators propose biotechnology tax credits - The State Journal-Register

Puma Biotechnology Inc (NYSE:PBYI) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Tuesday.

According to Zacks, Pumas progress with the lead candidate, neratinib, has been impressive. Currently, neratinib is under review in both the U.S. and the EU for the treatment of HER2-positive breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market. Several additional studies on neratinib targeting different types of breast cancer patient populations are currently underway. Being a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, the company is totally dependent on neratinib for growth. Puma has had its share of setbacks related to neratinib. With so much depending on the successful development and approval of neratinib, any further kind of development or regulatory setback could hamper the companys growth prospects and the stock adversely. Shares of the company have underperformed that of the industry in the past one year.

Other equities research analysts have also recently issued reports about the company. Citigroup Inc. set a $88.00 price target on Puma Biotechnology and gave the company a buy rating in a research note on Tuesday, January 3rd. Stifel Nicolaus reiterated a buy rating and issued a $88.00 price target on shares of Puma Biotechnology in a research note on Wednesday, November 30th. J P Morgan Chase & Co set a $89.00 price target on Puma Biotechnology and gave the company a buy rating in a research note on Monday, November 14th. Cowen and Company restated a market perform rating on shares of Puma Biotechnology in a research note on Tuesday, November 15th. Finally, Credit Suisse Group restated an outperform rating and set a $111.00 target price on shares of Puma Biotechnology in a research note on Tuesday, November 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $68.56.

Puma Biotechnology (NYSE:PBYI) traded up 0.73% on Tuesday, hitting $34.60. Puma Biotechnology has a one year low of $19.74 and a one year high of $73.27. The firms 50-day moving average is $37.28 and its 200-day moving average is $45.81. The companys market capitalization is $1.27 billion.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Canada Pension Plan Investment Board increased its position in shares of Puma Biotechnology by 53.2% in the third quarter. Canada Pension Plan Investment Board now owns 16,700 shares of the biopharmaceutical companys stock valued at $1,120,000 after buying an additional 5,800 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Puma Biotechnology by 112.0% in the third quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the biopharmaceutical companys stock valued at $143,000 after buying an additional 1,127 shares during the period. Northern Capital Management LLC increased its position in shares of Puma Biotechnology by 1.2% in the second quarter. Northern Capital Management LLC now owns 16,288 shares of the biopharmaceutical companys stock valued at $485,000 after buying an additional 190 shares during the period. Traynor Capital Management Inc. bought a new position in shares of Puma Biotechnology during the second quarter valued at about $246,000. Finally, JPMorgan Chase & Co. increased its position in shares of Puma Biotechnology by 31.4% in the second quarter. JPMorgan Chase & Co. now owns 231,875 shares of the biopharmaceutical companys stock valued at $6,907,000 after buying an additional 55,345 shares during the period. Institutional investors own 80.98% of the companys stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Read the original:
The Puma Biotechnology Inc (PBYI) Stock Rating Decreased by the Zacks Investment Research - DailyQuint

By: Express News Service | Mohali | Published:February 19, 2017 4:43 am The National Agri-Food Biotechnology Institute, Mohali, on Saturday observed its 7th foundation day.

The National Agri-Food Biotechnology Institute, Mohali, on Saturday observed its 7th foundation day at the NABI premises at Phase 8 in Mohali. The NABI is an autonomous institute aided by the department of Biotechnology, Government of India, and carries out research in the area of biotechnological applications at the intersection of agriculture, food and nutritional biotechnology.

Watch what else is making news:

A gathering of heads of the institutes and faculty from the Tricity region joined the function. More than 200 scientists, students and staff participated in the foundation day ceremony. Prof. Nagendra Kumar Singh, national professor, B P Pal chair and project director, ICAR National Research Centre on Plant Bioterchnology, New Delhi was the chief guest.

He delivered the foundation day lecture on Decoding the genomes of crop plants uniquely important for India. Dr T R Sharma, executive director, NABI highlighted the achievements of NABI and mentioned that NABI is poised to play an important role in generating world-class knowledge in the area of agri-food and health security. NABI is working on strategies to overcome anti-nutritional activity, and make food crops a better quality source for nutrition.

Go here to see the original:
National Agri-Food Biotechnology Institute celebrates seventh foundation day - The Indian Express

Xn`Dr(6bE3s8zfPF$=$;a{w|3%o !m~>ZxN&zUV2mMUt#rk75nLMmukVqnpC3B|l;#kjB|lFCQ|O3+ob9;]Kkt7+} Zx9GhBNz)Q;% m=Y# rwHj[p1_QVDCDbhA]kS^W_E]-0_.L,ka=4wlNa#.r=`GZ7&?zZO}O #:ZOzQ{4: i>|Ua/pN Zhh_$,maG>k!@V@F44LzO^5 LDAVqQq.!R_@Ol

+mYZQe,nFppP=1 u=uB~:= F'Iwv}%qJ a$xIOHr4gguI |xP_U7'G+q#pp"rL~:0]X~8gNDs/kO8T:U(4Xvo1%RDIc+xGY.gY>$">s0TK<8K@.H_Uzx HTwV-VNgNt)9~S< V3+= g3qiB;}q'mjk!yq*c~lLz?S-S@6vxbyT(@i joTAhk$f:D1Kfg+PhqhFc'#`YeU`bN.ywyi%u]8'QJ7t{M XafnC&Pu6gQX%'88V rh4uc?[dV=,-f'Y^dZF6zcN:-)8cy*DLz' 0kNdxpZLK4gEDYu49 NW4pXt-VdVZ%)2)C,snm)|[`pr 6k1/wg4lWM^B~&5Gj;Gj'+:rhYQavfS1Dz!_#jFW-*KYlQW8UQ ^;8E7Hz3%anh!t[3ujhqvh^z9Hki`h,aE>v)H;AL`J,8%Ycx!S~C^q5K"n]>K_Rh<;f8b9w5$ 9'kcY6C;@BI?f+-]/Emi>M% TWSEHBA`#X&n{_Q U44Sjep7#Qmj%r@r*$a9+bqB*3 _R9TMz12hAIz$;`Dr$7(DW`[PF`=Z,3{S ztVHKo 2sJ/#-Bx{ c:Oo5}>'8K 5 XV5`$ ]_yImJ=X?Az!L p fjE2ukU/BOc`1F~{S@Mn*%'J*@i{B PnKRX} Vp+v'6P8kt-/|CW,5!:N[gwerCm@o6sof4tiKllfGM :QEdr>+PBxncu|Hy;790j[6 YQqEL86n S`)Ux5]}ZEm,4{h27:kQ}WUq>t{YlKJ}qC GtG?!9-],wO`$eglA-4;>s )cSR_r_,%3OYS&4esxg/-Vd/cCjJv|D&rS6%rbH7Jq?uDp] {U uc]PnWnd8*#a7o]QY%#q.(z3HG{Fqk3(vF {W9(c>#}pTy: hW*X*4j6K.[JFe(x'Jo!gr"m8Mxs-M0FJ VH,8|YtYLm!$S*G8Yo;S=J;li`3&B^*I:1N14ONQ[6-NE=siTqOr [c Q !OCeBCAgG!%.q,z 7Tu/]tf:jS4qZM8c6!8DK4>q +A=6IU?33{,el%s!N2A19RF4ffE0I-``P/]=k0+<=A49)Cp>K0:@hs6ceP]%%VWpYHmGjvc`5nzFH:b$9Wkm|i#]4Xfgt?X_<<>p"p!=DBD) AN,4HOB = d*L)R_2qQe&ZD*5x@<[V){EbWT49?=x :t '@Qh@-=iEBP6rOSL KO>3~sY@BQu2R@CF>Jkt3dFoJoI?,L`MjY:)D SAz;sR5|H2m$H;HF/m}#ANPg[ep.e`5.~mBb

_}w1Zi:1kC;fG|cy SIKw(w{5_7j_8h_WPBt}tz} 6igh/*1TM=gjka[-3 }Yya9u>=NL5&t;b71m+xx=vpyy?P[a.&aF<)__mnOL[TB[kOW!v:r7M[kq_4qH1FSzY_1)Y&sy6yFRgy{; $7#&KTL]H/|(}Z"s,{Rl.n}xcf&9*9D{q{DN]]W0HqAB/{YHsZfW/7~W[f2q6nD/_w6/$iFnt9'riXF"Mrpc9&[ecI>#:G_N, v= y-N< Y)dw,e&YqM~tQ"cn/;.>6Y'BXHQ1.H#XmlB^RLM3Clw`#R[+8H"8,y +|l`${ EfXdTlFtsB{4,Z`cp4Mb'+fp @*ND)Sm??cT8R#2wV1k<>3 9xy qI DxW.K-~-%VtG&05XNz+W 5>'"T =1+f?pbB3*;0 5Z g 'jrnob }@wDk{#PN,3N$>4DFG;6*LUe]bBd2UNU UC3[6p%nY#@Q]D5:`dQ`'uc"7Nnifc=DZSHaE@yu mA%1R;CuIXt$V"[a}1./PU9(s!,vX$/(Aa%YLFOP pc6S{MHKx|9@,7e3H7:M7K^N!9Er6DjqjS7^T.Bz~,)qJ/:z?NSX:Qu@ akFL(,'$B{_!hN;qx )T8jvX,x?|0M(*I+AER`,lP#g(cP"$A@7tkTf`"G(Tq2j C' rNs}4Rs%` 7KH2X'P*AaC-Gx&6P`/,29-k00rFOtfzDbLQ^(F:NzG!BMS>0 hL`Rv#;m#HS_// Efg_DH9UK18^da(/tu:dh}H@n[M=_Ag 3X]HMKS EP&3c5LrLXT0i=Qz{`yfY iHHZ9< @qJi m'|`~)uWQ/~9?w:7JJ"#U];?/M"-7w')o=@VC4k#%mC-}}1(;I!.eF3KuJPfs8qn^uk1[7f5z(?m\Ch:?GykWU.=V~cyo7eq?%}R2}"]RzYjo+enQk`y&LfiB|! {^jh7j>uQ=^x; >% TlfcmX'5Bx|`!4j5AQV#4a($`*iQ/%][$s4.wV]"Ic[!8wk2_;H5]i9yGYjI5Lfu ^/z. oxLAMBPu=X"t]]C!{Kd{E*<)U?MoqG~N4W75=N,_|~H+>_>"Sj[CuIIa$;wW2>M- 'pQFZQKEl9Ut qX?H3Su `= (qY b{st$9EK$cnL1J7-YjM>{bT-5i+R0NfoZv ,Iv$h&jn"Ar2 `|B$.bPR94GfEO(oJQt%R&6NRZ@W^*h)m"HgJg)A&Q8hCo8n1`lZyS|'hTcV]]2~btE&4OGK.kC; $,l`Es!nM,I51P ek"[v+^4l.c5Z9ZP P!{?MnX H]un|{[lo 1z?,Qs 2C}k9|5D<>]FUw:5=*i?s/tq1]3@}~h^YPdc4!|KNRKGqQuN|;As8:LQVW9Kjc+EC]~F'/YLn5S_F[# ^xAw;gY0,H ~A0MJwur(Ky.NH0)t] 7)-Bv=]./8I?.79%T:}fReuAV41#ddxMeGT&K{I! % 0!r5"SUSdPFTUI]QhtO6P}IK*BFw!t`*~(xZ1+&Xj9u yQrzWA`j]2b9J6^!AQ-g vqq",'w;^fE&5am2z1?&c|wMgrhILxGvLPt':O,wj -cOSfo/el^"&T?TZ|qC rR?7RRZ A-pe/?i7M{thaiOTRli+:^q9I9/Rf.w.f|9(R`u!C}@InDQsco*{+g| n6_E/@CH]7|OWMc`|O>X_^x K> {|wP? }#<1l)..a9+=w}FCBt^opmz]rFS6PeS}apqBtj[mO/^j/]>{r-iCJ=sj!mo34_u,[YMECMgmpIkFUmA8?CuT'S %;JJYk]+!V^=p"QopVh~ky5e)QGJ<('yDT}faNaZvH1Yit~5-VkC@he3V7>9^r:Hm{) 4ica41 =w$;JaP:o2KFhxTSf}ZIA xqj7rFX.,ju1Lk7PsJ$RO979tJCnE^x*Mzy<-[L Mct' &gDNvoL8qqQ-T=]N?o:^x|M'SR[ (8F2 b`7&:ry$9;V6p}XMIE~( %^$2E](C8S WX{IXb9M t&xTVi;Qz0iu(MF0Z@iahFF'atF'atF &@i(SS}J @MCZ)n,o$ig>u% E=+D[`hPz Mmh&9[aT'iHm@hSw -P M&BcD0&Nha8g,R` 0:1 [`FX+0: MmhmBhuB'L(@<&4M`a &(m 1KsSetfCtdWPmtDik6PB$vEz;BBt@Z}`K 060:H71jlSQ7w>O-J$5 {/#=T]N{w*5bp?r*Oy 0_!V,l[%w>8f|y3 o'm`dw- d &WAt0}^4<#GcFu888|P(q(ZEd'9)#GYC,|rI1+Tpo8 5"%> v < "D`1j/iG?N$w>=D:j*wXAz)cUBaf'/h72p7 U~~J{~8-on~k+^O+MWd]4 cSHn0#2Dn~dciodDth,ZB+mt`(Sr0{0j(K"w +<)^A$UENqK- tQ)C3]Q (0KEm`H""G_QP0B2:9tXA)+5 N0 %d%ww]E7Qf;:IP ^>M>Cs_ }t*2,p{-w_L5a0jTh1W]qC {gB_cu mR%KcwFvrCqBCe|t EWc}}OLa3AtnC2v51Pq_o_pH*s%5M=bKqLq_^qzH~iv1'/n KgS5Xe JLa*w Ni.l}(9wbN[u<[H!(KC[)|D^C 1;A=bsO#^ lbCHXHW90j865FBSY(BnQuu6;"E7RI 0wHzlDDc ^SOPm4RD:?>;p&X^&cl4PnN6 y8 wN/ovD(SF3Ge-p&d;T#&yTaGuI|(s)%piy$xOJ@KHv;>iFdf*.nhb*wvCO"ddhwU;vddY"QKnUqGyX?SW. Hh v@zs#CqVvj[_ nOW#7vc!_z!A$72Wc"pWX^25wvnr='inJVwV6[ul5nX#-bO!X W hD (=bVzwtT6WVHrVEGvw{xE| X&Y .LSaKbpzs7"Nh+%_5=~I.AI>fWj[4MsG|g+]K8 /@E'Rm_@"jN?FfEUMI$L$T;Iiz8:,%oYn7]?G1' t|W?::jaB ~ +Wa^WntR"#(7A%Uo?x"M?8?D2Ko$2094$HqGC}rMle^*M U8v(%GE c_K)` SxEP)Rde+dbBF?xV_ -jI9,aH_0R_X:FbIxI3U!!L lJ7BU3eZcJi!e}$^r0/$q-M@T.|7+*]rRlB~()!dJ'U!!&eI!G8dc UddECz-0r/Jr.TJJ~t?2Ew, K,i{ ?>3GX`lZ}9c=EcYQ!|cOE1Jb:TT{W-]^4*j_x!_`wpUP/3CAH9r7Ua]6X7(CLjvv|? XY&Ll93j[)F?XqW#u}#yY-4y@l(v?=~fa~2y2>w0 >gPRPa.y$ALmPU%08R8&(SdidOKJn-]IE3H:SiKU.mp0rNWwm`K>?))vu^lw9DamaXF*xAj]K!j+r2VTT3U,) (l,erW46}xtB#NLq`d ;mBvya?1c"R5Cr )iqS+"%Oo9SFYPGuK8nC$Kq+1'tY3tW#yYaXT?%~c{;pOM28"lI Gwyd7P4lMc!j@8<&NcLerXn5Adn]=PL.8:X/SZ[t:R##jZOHX->?lyD}?9B$ ue

View post:
Hello, again, Dolly - The Economist

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Friday February 17 as shares jumped 7.76% to close at $40.25. About 1.37 million shares traded hands on 9,969 trades for the day, compared with an average daily volume of 928,303 shares out of a total float of 36.82 million. After opening the trading day at $37.25, shares of Puma Biotechnology Inc stayed within a range of $40.50 to $36.70.

With today's gains, Puma Biotechnology Inc now has a market cap of $1.48 billion. Shares of Puma Biotechnology Inc have been trading within a range of $73.27 and $19.74 over the last year, and it had a 50-day SMA of $34.47 and a 200-day SMA of $41.58.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 156 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continued here:
Puma Biotechnology Inc (PBYI) Soars 7.76% on February 17 ... - Equities.com

February 17, 2017 6:33am NASDAQ:IBB NYSE:XLV

From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF.

Likewise, the health stock market sector lost its status of outperformer as the XLV ETF went from 75 points to 62 points. Note that biotech is part of the health sector (XLV).

Biotechnology is now showing the first signs of life. The IBB ETF is up 3 percent on the week.

We warned readers to watch closely the 250 level in this alert: Biotechnology and Health Sector Testing Long Time Support. Later on, we noticed that biotech refused to break down, and started to show a pattern of higher lows. Right now, the biotech stock market sector is testing a breakout level. Things will really get bullish once 300 points in the IBB ETF is cleared.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) fell $1.78 (-0.61%) in premarket trading Friday. Year-to-date, IBB has gained 10.40%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

The broader healthcare sector (XLV ETF) looks even more interesting. It recovered its losses, and is now ready to test all-time highs. Make no mistake, 75 points is a very important price level. A triple-test is significant as, mostly, three tests are sufficient for a breakout. However, a failure to breakout, after 3 tests, is bearish to say the least.

The Health Care SPDR ETF (NYSE:XLV) was unchanged in premarket trading Friday. Year-to-date, XLV has gained 6.70%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

XLV currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #1 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Investing Haven.

Tags: biotech Health Care NASDAQ:IBB NYSE:XLV

Categories: NASDAQ:IBB NYSE:XLV

The rest is here:
iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB),Health ... - ETF Daily News (blog)

CRISPR is a life-changing genetic modification technology that could potentially cure cancer and eradicate genetic conditions before a child is born. But there is a dark side to the potential of this technology.

The patent dispute over CRISPR technology has been settled.

AN INFLUENTIAL US science advisory committee this week said genetic modification of human embryos should be allowed in the future to eliminate diseases, sparking new debate on a controversial topic.

The report by the National Academy of Sciences (NAS) caused concern among some researchers who fear that genetic tools could be used to boost certain peoples intelligence or create people with particular physical traits.

Clinical trials for genome editing of the human germ line adding, removing or replacing DNA base pairs in gametes or early embryos could be permitted in the future, said the report, released Wednesday (AEST).

But only, it added, for serious conditions under stringent oversight.

The emergence of inexpensive and accurate gene-editing technology, known as CRISPR/Cas9, has fuelled an explosion of new research opportunities and potential clinical applications, both heritable and non-heritable, to address a wide range of human health issues, the report said.

The committee of international experts was convened to examine scientific, ethical and governance issues surrounding human genome editing.

The experts noted that clinical trials on gene editing for certain non-hereditary traits are already under way.

These therapies affect only the patient, not any offspring, and should continue for treatment and prevention of disease and disability, using the existing ethical norms and regulatory framework for development of gene therapy, it said.

There is plenty of concern about the designer human floodgates opening.Source:YouTube

The warning come as a major patent battle over the technology was settled in the US in recent days.

What many described as the biotechnology trial of the century, the Broad Institute won the patent to the popular gene-editing process known as CRISPR/Cas-9.

The legal battle over who really invented the technology pitted Feng Zhang of the Broad Institute a research facility affiliated with Harvard University and the Massachusetts Institute of Technology against French microbiologist Emmanuelle Charpentier of the Max Planck Institute in Berlin and biochemist Jennifer Doudna of the University of California, Berkeley.

Both sides claimed to have developed CRISPR-Cas9, which allows scientists to edit stretches of the genome by removing, adding or changing pieces of the DNA sequence.

Jennifer Doudna of UC Berkeley ultimately lost out in the dispute.Source:Getty Images

Scientists say the technology has the potential to cure diseases but also raises ethical questions, particularly when it comes to the prospect of forever altering the human race.

Charpentier and Doudna have won multiple prizes in the past four years and were widely considered to have discovered this gene-editing technique. Their work was first published in the journal Science in June 2012.

This important decision affirms the inventiveness of the Broads work in translating the biology of the natural world into fundamental building blocks to create unprecedented medicines, said a statement by Katrine Bosley, president and chief executive officer of Editas Medicine, which has an exclusive licence on the Broad Institutes patent for human-therapy applications.

The Atlantic magazine described Editas Medicine as the biggest winner.

Assuming the patent decision does not change, Editas will be the major player in human CRISPR therapies in the foreseeable future, it said.

Excerpt from:
The biotechnology trial of the century over CRISPR patent settled in US court - NEWS.com.au

Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (Berlin: WTC) and CBDual Biotechnology Corp announced today that the two companies have reached a comprehensive cross-licensing agreement. This agreement covers intellectual property involving application of technology and process patents to produce high quality pharmaceutical grade cannabis materials. The patented technology facilitates the production of cannabinoid formulations that may include Cannabidiol (CBD) and Tetrahydrocannabinol (THC) that can be easily mixed into fluids or medications providing increased stability of products and a much quicker enhanced absorption rate of medications.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp. commented, "The cannabis derived products market is growing rapidly in North America. Market Research Future reports indicate that U.S., Canada, and Mexico are dominant markets for cannabis products and these markets are expected to grow at 33% per annum from 2016 to 2021. Growing awareness about cannabis medicinal properties is also reflected in growing demand for new CBD based products. The development of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. This is only possible if we use the most advanced technological processes and our agreement with CTi enables us to manufacture the best quality CBD based oral care products by utilizing their advanced patented technology."

Global Technology Manager of CTi, Roman Gordon, stated that, "Intellectual property covered by this agreement between our companies enhances the development of cannabis based products and helps us expand into new consumer and medical markets. Cannabis based medicine is now emerging and being revisited as a potential source of treatments for conditions not addressed properly by synthetic substances," concluded Mr. Gordon

CTi's cross-licensing arrangement with CBDual Biotechnology Corp will oversee the infusion of cannabinoids in CBD based oral healthcare product line that includes mouthwash, toothpaste with cannabidiol and other unique formulations. Management also sees the potential to attract a number of potential licensees and distributors across multiple markets, including the therapeutic foods, CBD water, dietary supplements and pharmaceutical industries.

About CTi

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement and water treatment. As an add-on to its existing neutralization systems, the company's patented Nano Reactor allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

http://www.ctinanotech.com/

About CBDual Biotechnology Corp.

CBDual Biotechnology is a privately held, US based Biotechnology company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquarted in California with its R&D capability in Israel and Ukraine.

CBDual Biotechnology is a pharmaceutical research and development company, focused on the commercialization of cannabinoids (CBD) based oral hygiene products and for the treatment of gum disease, bad breath, pain and other disorders associated with oral health, including CBD mouthwash, CBD toothpaste and other unique pharmaceutical products. Company conducts medical research and clinical trials in their new clinical research center in California. Company's Medical Advisory Board has experienced, Board certified doctors and specialists that oversee and design clinical research and develop new products.

Welcome to CBDual

Forward Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Cavitation Technologies, Inc.

Contact:

Investor Relations Jessica Steidinger Jessica@ctinanotech.com Phone (818) 718-0905

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read more:
Cavitation Technologies, Inc. (CVAT) Announces Cross Licensing ... - Equities.com